乳腺癌患者血清GDF-15、SKA3、HMGA2的表达水平及其与化疗疗效的相关性  

Expression levels of serum GDF-15,SKA3,and HMGA2 in breast cancer patients and their correlation with the efficacy of chemotherapy

作　　者：王娅 刘平贤[2] 魏昱博 刘梦月 杜新峰[1] WANG Ya;LIU Ping-xian;WEI Yu-bo;LIU Meng-yue;DU Xin-feng(Department of Mammary Gland,Nanyang Central Hospital,Nanyang 473000,Henan,CHINA;Department of Joint Surgery and Sports Medicine,Nanyang Central Hospital,Nanyang 473000,Henan,CHINA)

机构地区：[1]南阳市中心医院乳腺科,河南南阳473000 [2]南阳市中心医院关节外科运动医学一病区,河南南阳473000

出　　处：《海南医学》2025年第7期1008-1013,共6页Hainan Medical Journal

基　　金：2022年河南省医学科技攻关联合共建项目(编号:LHGJ20222051)。

摘　　要：目的检测乳腺癌患者中血清生长分化因子15(GDF-15)、纺锤体与着丝粒相关蛋白3(SKA3)、高迁移率蛋白A2(HMGA2)水平,并分析其与化疗疗效的相关性。方法前瞻性选取2021年5月至2023年5月南阳市中心医院收治的130例乳腺癌患者纳入研究,比较不同临床病理特征患者的血清GDF-15、SKA3、HMGA2表达水平,采用Spearman法分析血清GDF-15、SKA3、HMGA2表达水平与临床病理特征的相关性。依据化疗4个周期后化疗效果将患者分为有效组94例和无效组36例,比较两组患者化疗前后的血清GDF-15、SKA3、HMGA2水平。采用受试者工作特征(ROC)曲线分析化疗前血清GDF-15、SKA3、HMGA2对化疗疗效的预测价值。采用RR相对危险度分析血清GDF-15、SKA3、HMGA2与化疗疗效的相关性。结果临床分期Ⅲ期、组织低分化、发生淋巴结转移者的血清GDF-15、SKA3、HMGA2表达水平明显高于临床分期Ⅱ期、组织中高分化、未发生淋巴结转移者,差异均有统计学意义(P<0.05);Spearman分析结果显示,血清GDF-15、SKA3、HMGA2水平与临床分期、组织分化程度、淋巴结转移呈正相关(P<0.05);化疗前有效组患者的血清GDF-15、SKA3、HMGA2水平分别为(2.19±0.61)μg/L、(35.02±6.73)pg/mL、(227.53±60.52)mg/L,明显低于无效组的(2.59±0.67)μg/L、(47.51±7.55)pg/mL、(253.06±62.38)mg/L,差异均有统计学意义(P<0.05);化疗4个周期后有效组患者的血清GDFP<15、SKA3、HMGA2水平分别为(1.96±0.52)μg/L、(30.22±4.94)pg/mL、(203.59±50.28)mg/L,明显低于无效组的(2.21±0.57)μg/L、(36.27±5.62)pg/mL、(224.18±53.69)mg/L,差异均有统计学意义(P<0.05);ROC分析结果显示,化疗前血清GDF-15、SKA3、HMGA2单项及联合预测乳腺癌患者化疗疗效的AUC分别为0.768、0.779、0.788、0.898,敏感度分别为80.56%、77.78%、75.00%、86.11%,特异度分别为63.83%、69.15%、74.47%、82.98%;RR相对危险度分析结果显示,血清GDF-15>1.98μg/L、SKA3>43.83 pg/mL、HMGA2>234.5Objective To detect the levels of serum growth differentiation factor 15(GDF-15),spindle and centromere-associated protein 3(SKA3),and high mobility group A2(HMGA2)in breast cancer patients,and analyze their correlation with chemotherapy efficacy.Methods A total of 130 breast cancer patients admitted to Nanyang Central Hospital from May 2021 to May 2023 were prospectively selected and included in the study.The expression levels of serum GDF-15,SKA3,and HMGA2 were compared in patients with different clinical pathological characteristics.Spearman method was used to analyze the correlation between the expression levels of serum GDF-15,SKA3,and HMGA2 and clinical pathological characteristics.Based on the efficacy of chemotherapy after 4 cycles,patients were divided into an effective group of 94 cases and an ineffective group of 36 cases.The levels of serum GDF-15,SKA3,and HMGA2 were compared between the two groups before and after chemotherapy.The predictive value of serum GDF-15,SKA3,and HMGA2 levels before chemotherapy for the efficacy of chemotherapy was analyzed using the receiver operating characteristic(ROC)curve.The correlation between serum GDF-15,SKA3,and HMGA2 and the efficacy of chemotherapy was analyzed using RR relative risk analysis.Results The expression levels of serum GDF-15,SKA3,and HMGA2 in patients with clinical stageⅢ,low tissue differentiation,and lymph node metastasis were significantly higher than those in patients with clinical stageⅡ,high tissue differentiation,and no lymph node metastasis,with statistically significant differences(P<0.05).Spearman analysis results showed that the levels of serum GDF-15,SKA3,and HMGA2 were positively correlated with clinical stage,tissue differentiation degree,and lymph node metastasis(P<0.05).The levels of serum GDF-15,SKA3,and HMGA2 in the effective group before chemotherapy were(2.19±0.61)μg/L,(35.02±6.73)pg/mL,and(227.53±60.52)mg/L,respectively,which were significantly lower than(2.59±0.67)μg/L,(47.51±7.55)pg/mL,and(253.06±62.38)mg/L in the i

关 键 词：乳腺癌 生长分化因子15 纺锤体与着丝粒相关蛋白3 高迁移率蛋白A2 化疗 疗效 预测 

分 类 号：R737.9[医药卫生—肿瘤]